

**Sterne Kessler
Goldstein Fox**



Robert Greene Sterne
Edward A. Kessler
George A. Goldstein
David K. Goldstein
Robert W. Edmund
Tracy Daniels Dunkin
Michael A. Lombard
Michael B. Ray
Robert E. Sukoff
Eric K. Steffe
Michael G. Lee
Steven R. Ludwig
John M. Covert
Linda E. Adorn
Robert C. Milberg
Lawrence B. Budzinski
Donald J. Feinbaum
Michael J. Messenger

Ludwig K. Kim
Timothy J. Meador
Patricia E. Hanft
Jeffery T. Hevey
Heidi L. Kraus
Crystal D. Naves
Edward W. Yee
Albert J. Ferris
Donald R. Bandow
Peter A. Jackman
Molly A. McFall
Teresa L. Meder
Jeffrey S. Weaver
Kenneth R. Patters
Vincent J. Caputo
Albert J. Fasulo
C. D. E. E. E. E. E. E.
W. Russell Swindle

Thomas J. Kida
Brian J. De Busch
John Lee Beasly
Reginald J. Cowan
Kimberly A. Reddy
Theodore A. Wood
Elizabeth J. Madies
Bruce E. Chalkin
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Chouler
Rae Lynn Pengamant
Jane Shersherovich
Lawrence J. Carroll
Venerio Spence
Samuel J. Kirk
Kenneth C. Bass

Registered Patent Agent
Karin R. Matkovic
Andrea J. Kattagiri
Nancy J. Leith
Joseph M. Corns
Ann E. Summerfield
Heleen C. Carlson
Gaby L. Longworth
Matthew J. Dowd
Aaren L. Schwartz
Angelique G. Ly
Boris A. Matvienko
Mark B. Tard

*Admitted only in Maryland
*Admitted only in Virginia
*Admitted only in Texas

March 11, 2002

WRITER'S DIRECT NUMBER:
(202) 371-2609

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

MAR 13 2002

Group Art Unit 1647

TECH CENTER 1600.2900

Re: U.S. Utility Patent Application
Appl. No. 09/722,495: Filed: November 28, 2000
For: **Analog of Human basic Fibroblast Growth Factor**
Inventors: Springer *et al.*
Our Ref: 1503.0220002/JAG/THN

RECEIVED

MAR 12 2002

TC 1700

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449 (17 sheets); and
3. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
March 11, 2002
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency,
or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE KESSLER, GOLDSTEIN & FOX P.L.L.C.

Jorge A. Goldstein
Attorney for Applicants
Registration No. 29,021


Enclosures

P:\USERS\TARJAHN\1503\1503.0220002\pto\IDS\TRANS.WPD

RECEIVED

MAR 13 2002

TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SPRINGER *et al*

Appl. No. 09/722,495

Filed: November 28, 2000

For: **Analog of Human basic
Fibroblast Growth Factor**

Confirmation No. 5579

Art Unit: 1647

Examiner: Saoud, C.

Atty. Docket: 1503.0220002/JAG/THIN

Information Disclosure Statement

RECEIVED

MAR 1 2 2002

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

TC 1700

MAR 1 3 2002

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted

herewith. It is further understood that the Examiner will consider information that had been cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Copies of the documents were cited by and submitted to the Office in Applicants' Information Disclosure Statement that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 09/826,210, filed April 5, 2001. Further to a telephonic conference on February 19, 2002, between Examiner Gary Koons and Tarja H. Naukkarinen of Sterne, Kessler, Goldstein & Fox, copies of the cited documents are not attached. If the Examiner does not have access to the copies of the cited documents, the Examiner is hereby invited to request the copies from the undersigned attorney of record.

This Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Jorge A. Goldstein
Attorney for Applicants
Registration No. 29,021

Date: _____

3/11/02

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600